Net shares · 365d
-212.9K
0 buy · 212.9K sell
Net value · 365d
-$929.9K
$0 in · $929.9K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
4
0 buy · 212.9K sell
Trading track record · all companies
Not enough open-market trades to chart a track record yet.
Running net of open-market buys − sells across every company. Tap the line or a marker for details. ▲ buy · ▼ sell.
Transactions · 365d
-
RXRX Sell·S
CEO and President · 10b5-1
$84.5K
23.6K sh · $3.58
Own -1%
-
RXRX Other·F
CEO and President
$190.6K
62.7K sh · $3.04
Own -3%
-
RXRX Sell·S
CEO and President · 10b5-1
$94.8K
28.3K sh · $3.35
Own -1%
-
RXRX Other·F
CEO and President
$49.8K
14.3K sh · $3.49
Own -1%
-
RXRX Other·F
CEO and President
$41.2K
10.4K sh · $3.98
Own -0%
-
RXRX Grant·A
CEO and President
$0
1.7M sh · 2 lots
Own +293%
-
RXRX Sell·S
Chief R&D Commercial Officer · 10b5-1
$548.6K
124.4K sh · $4.41
Own -17%
-
RXRX Other·F
Chief R&D Commercial Officer
$72.8K
17.6K sh · $4.14
Own -2%
-
RXRX Grant·A
Chief R&D Commercial Officer
$0
169.9K sh
Own New
-
RXRX Grant·A
Chief R&D Commercial Officer
$0
84.9K sh
Own +13%
-
RXRX Sell·S
Chief R&D Commercial Officer
$202.0K
36.6K sh · $5.52
Own -5%
-
RXRX Other·F
Chief R&D Commercial Officer
$21.4K
3.8K sh · $5.64
Own -1%
| Date▾ | Ticker | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | RXRX | Sell S | 23.6K | $84.5K |
| May 15, 2026 | RXRX | Other F | 62.7K | $190.6K |
| Mar 9, 2026 | RXRX | Sell S | 28.3K | $94.8K |
| Feb 17, 2026 | RXRX | Other F | 14.3K | $49.8K |
| Feb 6, 2026 | RXRX | Other F | 10.4K | $41.2K |
| Feb 6, 2026 | RXRX | Grant A | 1.7M2 lots | $0 |
| Dec 22, 2025 | RXRX | Sell S | 124.4K | $548.6K |
| Nov 17, 2025 | RXRX | Other F | 17.6K | $72.8K |
| Nov 5, 2025 | RXRX | Grant A | 169.9K | $0 |
| Nov 5, 2025 | RXRX | Grant A | 84.9K | $0 |
| Aug 18, 2025 | RXRX | Sell S | 36.6K | $202.0K |
| Aug 15, 2025 | RXRX | Other F | 3.8K | $21.4K |
Buy Sell Non-market (grant · exercise · gift)
About Khan Najat
This profile aggregates every SEC Form 4 insider transaction reported by Khan Najat across all companies they trade. Open-market purchases (code P) and sales (code S) are the highest-signal, discretionary trades; grants (A), option exercises (M) and gifts (G) reflect compensation rather than conviction and carry no market price. Figures cover the selected period and update as new filings are ingested.